C. Shih, V. J. Chen, L. S. Gossett, et al., “LY231514, a Pyrrolo[2,3-d]Pyrimidine-Based Antifolate That Inhibits Multiple Folate-Requiring Enzymes,” Cancer Research, Vol. 57, No. 6, 1997, pp. 1116-1123.
 C. Cripps, M. Burnell, J. Jolivet, et al., “Phase II Study of First-Line LY231514 (Multi-Targeted Antifolate) in Patients with Locally Advanced or Metastatic Colorectal Cancer: An NCIC Clinical Trials Group Study,” Annals of Oncology, Vol. 10, 1999, pp. 1175-1179. doi:10.1023/A:1008372529239
 W. John, J. Picus, C. D. Blanke, et al., “Activity of Multitargeted Antifolate (Pemetrexed Disodium, LY231514) in Patients with Advanced Colorectal Carcinoma: Results from a Phase II Study,” Cancer, Vol. 88, No. 8, 2000, pp. 1807-1813. doi:10.1002/(SICI)1097-0142(20000415)88:8<1807::AID-CNCR8>3.0.CO;2-L
 C. Underhill, D. Goldstein, V. A. Gorbounova, et al., “A Randomized Phase II Trial of Pemetrexed plus Irinotecan (ALIRI) versus Leucovorin-Modulated 5-FU plus Irinotecan (FOLFIRI) in First-Line Treatment of Locally Advanced or Metastatic Colorectal Cancer,” Oncology, Vol. 73, No. 1-2, 2007, pp. 9-20. doi:10.1159/000120626
 S. R. Alberts, G. P. Kim, M. R. Mahoney, et al., “Pemetrexed and Oxaliplatin for Metastatic Colorectal Cancer: Results of a Phase I Mayo Cancer Center Research Consortium Trial, MC0248,” Clinical Colorectal Cancer, Vol. 6, No. 8, 2007, pp. 572-577. doi:10.3816/CCC.2007.n.024
 J. N. Atkins, S. A. Jacobs, H. S. Wieand, et al., “Pemetrexed/Oxaliplatin for First-Line Treatment of Patients with Advanced Colorectal Cancer: A Phase II Trial of the National Surgical Adjuvant Breast and Bowel Project Foundation Research Program,” Clinical Colorectal Cancer, Vol. 5, No. 3, 2005, pp. 181-187. doi:10.3816/CCC.2005.n.029
 R. Paulson, R. Paulson, J. Hainsworth, C. Geyer, et al., “A Phase II Trial of MTA (Multiple Targeted Antifolate, LY231514) in Patients with 5-FU and Irinotecan-Refractory Colorectal Cancer,” American Society of Clinical Oncology, Vol. 18, 1999, 297a.
 D. A. Rinaldi, H. A. Burris, F. A. Dorr, et al., “Initial Phase I Evaluation of the Novel Thymidylate Synthase Inhibitor, LY231514, Using the Modified Continual Reassessment Method for Dose Escalation,” Journal of Clinical Oncology, Vol. 13, No. 11, 1995, pp. 2842-2850.
 M. Merl, C. Hoimes, T. Pham, et al., “Is There a Palliative Benefit of Gemcitabine plus Fluoropyrimidines in Patients with Refractory Colorectal Cancer?” Expert Opinion on Investigational Drugs, Vol. 18, No. 9, 2009, pp. 257-1264. doi:10.1517/13543780903136724
 J. L. Tonkinson, J. F. Worzalla, C. H. Teng, et al., “Cell Cycle Modulation by a Multitargeted Antifolate, LY231514, Increases the Cytotoxicity and Antitumor Activity of Gemcitabine in HT29 Colon Carcinoma,” Cancer Research, Vol. 59, No. 15, 1999, pp. 3671-3676.
 A. Tesei, L. Ricotti, F. De Paola, et al., “In Vitro Schedule-Dependent Interactions between the Multitargeted Antifolate LY231514 and Gemcitabine in Human Colon Adenocarcinoma Cell Lines,” Clinical Cancer Research, Vol. 8, No. 1, 2002, pp. 233-239.
 T. M. De Pas, F. Toffalorio, C. Catania, et al., “Gemcitabine and Pemetrexed Combination: The Key Role of the Sequence of Drugs Administration,” Annals of Oncology, Vol. 20, No. 10, 2009, pp. 1747-1748. doi:10.1093/annonc/mdp385
 C. X. Ma, S. Nair, S. Thomas, et al., “Randomized Phase II Trial of Three Schedules of Pemetrexed and Gemcitabine as Front-Line Therapy for Advanced Non-SmallCell Lung Cancer,” Journal of Clinical Oncology, Vol. 23, No. 25, 2005, pp. 5929-5937. doi:10.1200/JCO.2005.13.953
 K. L. Spindler, N. Pallisgaard, I. Vogelius, et al., “Quantitative Cell Free DNA, KRAS and BRAF Mutations in Plasma from Patients with Metastatic Colorectal Cancer during Treatment with Cetuximab and Irinotecan,” Clinical Cancer Research, Vol. 18, No. 4, 2012, pp. 1177-185. doi:10.1158/1078-0432.CCR-11-0564
 R. Ferrarotto, K. Machado, M. P. Mak, et al., “A Multicenter, Multinational Analysis of Mitomycin C in Refractory Metastatic Colorectal Cancer“, European Journal of Cancer, Vol. 48, No. 6, 2012, pp. 820-826. doi:10.1016/j.ejca.2012.01.008
 M. G. Fakih, A. Groman, J. McMahon, et al., “A Randomized Phase II Study of Two Doses of Vorinostat in Combination with 5-FU/LV in Patients with Refractory Colorectal Cancer,” Cancer Chemotherapy and Pharmacology, Vol. 69, No. 3, 2012, pp. 743-751.
 H. Yasui, T. Yoshino, N. Boku, et al., “Retrospective Analysis of S-1 Monotherapy in Patients with Metastatic Colorectal Cancer after Failure to Fluoropyrimidine and Irinotecan or to Fluoropyrimidine, Irinotecan and Oxaliplatin,” Japanese Journal of Clinical Oncology, Vol. 39, No. 5, 2009, pp. 315-320.